Clinical and laboratory studies of 2-chlorodeoxyadenosine ± cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults

Leukemia

Volumn 10, Issue 10, 1996, Pages 1563-1569

  Kornblau, S M ^a   Gandhi, V ^a   Andreeff, H M ^a   Beran, M ^a   Kantarjian, H M ^a   Koller, C A ^a   O'Brien, S ^a   Plunkett, W ^a   Estey, E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

2CdA; Adults; Ara C; Pharmacology; Relapsed AML

Indexed keywords

CLADRIBINE; CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; BLAST CELL; BLEEDING; BONE MARROW HYPOPLASIA; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACCUMULATION; DRUG UPTAKE; HUMAN; HUMAN CELL; INFECTION; KIDNEY DISEASE; LYMPHOPROLIFERATIVE DISEASE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0029744389     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Chunduru SK, Appleman JR, Blakeley RL. Activity of human DNA polymerase α and β with 2-chloro-2′-deoxyadenosine triphosphate as a substrate and quantitative effects of incorporation on chain extension. Arch Biochem Biophys 1993; 302: 19-30.
2. Parker WB, Shaddix SC, Chang C-H, White L, Rose LM, Brockman W, Shortnacy AT, Montgomery JA, Secrist JA, Bennett LL Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphates. Cancer Res 1991; 51: 2386-2394.
3. Beutler E, Piro LD, Saven A, Kay AC, McMillan R, Longmire R, Carrera CJ, Morin P, Carson DA. 2-chlorodexyadenosine (2-CdA): a potent chemotherapeutic and immunosuppressive nucleoside. Leuk Lymphoma 1991; 5: 1-8.
4. Carson DA, Wasson B, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 1983; 62: 737-743.
5. Estey EH, Kurzrock R, Kantarjian HM, O'Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg CH, Huh YO, Stass S, Freireich EJ. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2CdA). Blood 1992; 79: 882-887.
6. Tallman MS, Hakimian D, Variakojis D, Koslow D, Sisney GA, Rademaker AW, Rose E, Kaul K. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia. Blood 1992; 80: 2203-2209.
7. Juliusson G, Elmhorn-Rosenborg A, Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. New Engl J Med 1992; 327: 1056-1061.
8. O'Brien SM, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood 1994; 84: 733-738.
9. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994; 120: 784-791.
10. Dimopoulos MA, Kantarjian H, Estey E, O'Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993; 118: 195.
11. Saven A, Piro LD, Lemon RH, Figueueroa ML, Kosty M, Ellison DJ, Beutler E. Complete hematologic remissions in chronic-phase Philadelphia-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 1994; 73: 2953-2963.
12. Santana VM, Mirro J, Harwood FC, Cherrie J, Schell M, Kalwinsky D, Blakeley RL. A phase 1 clinical trial of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia. J Clin Oncol 1991; 9: 416-422.
13. Santana VM, Mirro J Jr, Kearns C, Schell MJ, Crom W, Blakley RL. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J Clin Oncol 1992; 10: 364-370.
14. Santana VM, Hurwitz CA, Blakeley RL, Crom WR, Luo X, Roberts M, Ribeiro R, Mahmoud H, Krance RA. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myelogenous leukemia. Blood 1994; 84: 1237-1242.
15. Vahdat L, Wong EG, Wile MJ, Rosenblum M, Foley KM, Warrell RP Jr. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994; 84: 3429-3434.
16. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993; 11: 116-124.
17. Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 1992; 52: 897-903.
18. Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 1994; 34: 30-36.
19. Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating MJ. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer 1993; 72: 2155-2160.
20. Gandhi V, Plunkett W. Modulation of arabinosyl nucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988; 48: 329-334.
21. Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood 1996; 87: 256-264.
22. Kristensen J, Nygren P, Liliemark J, Fridborg H, Killander A, Simonsson B, Oberg G, Larsson R. Interactions between cladarabine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia 1994; 8: 1712-1717.
23. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1996; 50: 219-244.
24. Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ. Saturation of 1-β-D-arabinosylcytosine 5′-triphosphate accumulation in leukemic cells during high dose 1-β-D-arabinosylcytosine therapy. Cancer Res 1987; 47: 3005-3011.
25. Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during high-dose ara-C therapy. Phamacologic rational for intermediate-dose ara-C. Semin Oncol 1987; 14 (Suppl. 1): 159.
26. Plunkett W, Hug V, Keating MJ, Chubb S. Quantitation of 1-β-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-β-D-arabinofuranosylcytosine therapy. Cancer Res 1980; 40: 588-591.
27. Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma 1993; 9: 343-350.
28. Gandhi V, Danhauser L, Plunkett W. Separation of 1-β-D-arabinofuranosyl-2-fluoroadenine 5′-triphosphate in human leukemic cells by high performance liquid chromatography. J Chromatogr 1987; 413: 293-299.
29. Thall PF, Estey E. A Bayesian strategy for screening cancer treatments prior to phase II evaluation. Stat Med 1993; 12: 1197-1211.
30. Liliemark J, Juliusson G. Cellular pharmacokinetics of 2-chloro-2′ deoxyadenosine nucleotides: comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients. Clin Cancer Res 1995; 1: 385-390.
31. Davis CL, Rohatiner AZS, Lim J, Whelan JS, Oza AM, Amess J, Love S, Stead E, Lister TA. The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period. Br J Haematol 1993; 83: 404-411.
32. Dutcher JP, Leong T, Makary AZ, Bennett J, Frontiera M, Miller H, Wiernik PH. A phase II study of menogaril (7R-O-methylnogarol) in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 1995; 9: 1638-1642.